RGPX
REGENEREX PHARMA, INC.CIK 0001357878 · SIC 2834 · Pharmaceutical Preparations
Regenerex Pharma, Inc. (the "Company" or "Regenerex Pharma") specializes in the development and commercialization of advanced wound care healing products. The Company operates through three distinct proprietary technologies designed to address different wound care needs: About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade RGPX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Nov 17, 2025 (period ending Sep 30, 2025). As printed on the EDGAR/iXBRL face — not generated by the model.
Statements of Operations (Unaudited)
| Description | Three months ended September 30, 2025 | Three months ended September 30, 2024 | Six months ended September 30, 2025 | Six months ended September 30, 2024 |
|---|---|---|---|---|
| Operating Expenses | ||||
| General and administrative | 650,277 | 258,384 | 1,286,987 | 512,664 |
| Research and development | 136,432 | — | 133,506 | — |
| Total Operating Expenses | 786,709 | 258,384 | 1,420,493 | 512,664 |
| Operating Loss | (786,709) | (258,384) | (1,420,493) | (512,664) |
| Other Income (Expense) | ||||
| Interest expense | (22,713) | (266,157) | (46,309) | (288,490) |
| Foreign currency gain (loss) | (539) | (5,031) | (6,631) | (978) |
| Other expense | (4,000) | — | (4,000) | — |
| Taxes | (50) | — | (163) | — |
| Total Other Income (Expense) | (27,302) | (271,188) | (57,103) | (289,468) |
| Net Loss | (814,011) | (529,572) | (1,477,596) | (802,132) |
| Basic and Diluted Loss per Common Share | (0.00) | (0.00) | (0.00) | (0.00) |
| Weighted Average Number of Common Shares Outstanding | 281,463,410 | 278,281,562 | 281,410,910 | 278,254,052 |
Balance Sheets (Unaudited)
| Description | September 30, 2025 | March 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash and equivalents | 11,659 | 653,025 |
| Prepaid expenses | 36,770 | 350 |
| Total Current Assets | 48,429 | 653,375 |
| Capitalized Software Development | 38,472 | — |
| Furniture and computer equipment, net of accumulated depreciation of $5,743 and $3,326 as of September 30, 2025 and March 31, 2025 | 3,628 | 5,599 |
| Right of use assets | 527,235 | 604,262 |
| Total Assets | 617,764 | 1,263,236 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current Liabilities | ||
| Accounts payable | 218,748 | 197,673 |
| Related party advances | — | 13,652 |
| Accrued compensation | 808,276 | 842,620 |
| Other accrued liabilities | 154,357 | 88,268 |
| Current portion of notes payable to shareholder | 488,797 | 469,105 |
| Current portion of notes payable to related parties | 214,584 | 306,103 |
| Current portion of notes payable | 2,847,737 | 2,824,232 |
| Current portion of lease liabilities | 191,181 | 181,894 |
| Total Current Liabilities | 4,923,680 | 4,923,547 |
| Lease liabilities, net of current portion | 392,884 | 495,894 |
| Total Liabilities | 5,316,564 | 5,419,441 |
| Commitments and Contingencies (Note 7) | — | — |
| Stockholders’ Deficit | ||
| Common stock: $0.001 par value; 675,000,000 shares authorized; 281,750,910 and 281,070,910 issued and outstanding at September 30, 2025 and March 31, 2025 | 281,751 | 281,071 |
| Additional paid-in capital | 4,639,935 | 3,705,615 |
| Accumulated deficit | (9,620,486) | (8,142,891) |
| Total Stockholders’ Deficit | (4,698,800) | (4,156,205) |
| Total Liabilities and Stockholders’ Deficit | 617,764 | 1,263,236 |
Statements of Cash Flows (Unaudited)
| Description | Six months ended September 30, 2025 | Six months ended September 30, 2024 |
|---|---|---|
| Cash Flows from Operating Activities: | ||
| Net loss | (1,477,596) | (802,132) |
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||
| Depreciation and amortization | 2,416 | 1,985 |
| Foreign currency adjustment | 6,631 | 978 |
| Stock-based compensation | 435,000 | 56,795 |
| Non-cash extension fee to Greenwich Resources | — | 240,000 |
| Amortization of ROU assets, net of liabilities | (16,696) | 26,504 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | (36,420) | 999 |
| Accounts payable | 21,076 | 70,086 |
| Accrued compensation | (34,343) | 193,770 |
| Other accrued liabilities | 102,634 | 29,077 |
| Net cash used in operating activities | (997,298) | (181,938) |
| Cash Flows from Investing Activities: | ||
| Capitalized Software Development | (38,472) | — |
| Purchase of furniture and computer equipment | (446) | — |
| Net cash used in investing activities | (38,918) | — |
| Cash Flows from Financing Activities: | ||
| Repayment of notes payable to related parties | (105,150) | — |
| Proceeds from notes payable to related parties | — | 131,860 |
| Proceeds from sale of common stock and warrants | 500,000 | 50,000 |
| Net cash provided by financing activities | 394,850 | 181,860 |
| Increase (decrease) in cash and equivalents | (641,366) | (78) |
| Cash and cash equivalents, beginning of period | 653,025 | 372 |
| Cash and cash equivalents, end of period | 11,659 | 294 |
| Supplemental Cash Flow Information – Cash Paid For: | ||
| Income taxes | — | — |
| Interest | — | — |
| Non-Cash Investing and Financing Activities: | ||
| Accrued interest converted into note payable to shareholder | 23,467 | 26,662 |
| Accrued interest converted into note payable to related parties | 13,631 | 5,616 |
| Accrued interest converted into note payable | 23,505 | — |
| Note payable for interest expense | — | 240,000 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
About REGENEREX PHARMA, INC.
Source: Item 1 (Business) from the 10-K filed June 30, 2025. Description as filed by the company with the SEC.
ITEM 1. BUSINESS.
Business of Issuer
Company Overview
Regenerex Pharma, Inc. (the "Company" or "Regenerex Pharma") specializes in the development and commercialization of advanced wound care healing products. The Company operates through three distinct proprietary technologies designed to address different wound care needs:
1.
Chronic Wound Closure Technology - Specifically designed for closing chronic wounds
2.
Acute Wound Acceleration Technology - Focused on accelerating closure of acute or surgical wounds
3.
Contamination Control Technology - Addresses contamination issues across all wound types, including biofilm destruction
Product Portfolio
The Company's comprehensive Wound Closure System and protocols effectively treat a broad spectrum of wounds, including diabetic ulcers, pressure ulcers, venous ulcers, burns, and surgical wounds. These innovative products position Regenerex to capture significant market share in both domestic and international markets.
Core Technology: QBx™
The Company's proprietary active ingredient, QBx™, addresses a critical issue in wound healing by down-regulating the production of specific proteases and matrix metalloproteases (MMPs). Medical and scientific consensus has established that elevated protease levels significantly impede wound healing, with approximately 80% of chronic wounds displaying elevated protease levels, including MMPs.
Current Products
1.
Xcellderma™ OTC - Liquid Bandage Skin Protectant
a.
Sterile wound dressing effective for treating wounds, skin irritations, cuts, and abrasions
Read full description ↓
b.
Available as an over-the-counter solution
2.
Accelerex™ Sterile Wound Cream
a.
First commercially available medical device containing QBx™
b.
Designed for treating chronic and acute wounds including:
o
Diabetic ulcers
o
Burns
o
Pressure ulcers (stages I-IV)
o
Venous stasis ulcers
•
Custom-formulated sterile wound ointment utilizing technology originally derived from oak bark extract
6
Market Opportunity
Clinical Efficacy
QBx™ represents the most efficacious, clinically proven chronic wound care technology globally. The Company's Wound Closure System has demonstrated remarkable success in clinical trials, achieving closure rates of up to 95% of non-responding chronic wounds within 90 days. Notably, these tested wounds had previously failed to respond to conventional treatment protocols.
Market Need
Chronic wounds represent a significant healthcare challenge characterized by:
•
Failure to progress through normal healing sequences
•
Delayed healing lasting weeks, months, or years
•
Resistance to conventional dressings and therapies
•
Substantial financial and quality-of-life burden on patients
•
Frustration for caregivers and clinicians
These wounds typically become trapped in a catabolic, inflammatory phase hostile to growth factors and cellular repair mechanisms. Traditional treatments using gauze and modern dressings (hydrocolloids, collagens) fail to address the underlying cellular environment, creating a significant market opportunity.
Economic Impact
Chronic wounds impose substantial costs on the U.S. healthcare system:
•
Nearly seven million Americans currently live with chronic wounds
•
One in four families has a member with a chronic wound
•
3% of individuals over 65 have open wounds
•
Growing prevalence due to aging population and increasing rates of diabetes and obesity
Regulatory and Market Environment
The Affordable Care Act (ACA) has fundamentally changed wound care reimbursement structures, transitioning all market segments—hospitals, nursing homes, home health, and wound care clinics—to pay-for-performance models. This shift creates significant opportunities for cost-effective, high-performance solutions like the Company's Wound Closure System.
Home health providers now receive single diagnostic code payments, transferring financial risk from payees to payers. The Company is strategically targeting market segments operating under these "at-risk" payment models, with home health and nursing homes representing the fastest-growing segments due to demographic trends.
7
Operations and Manufacturing
The Company has established manufacturing capabilities through:
•
Purchase of proprietary wound care formulations
•
Lease agreement dated June 10, 2023, with Woundcare Labs, LLC for plant and equipment in Tennessee
•
Current FDA clearance for Xcellderma™ manufacturing
•
Ongoing FDA re-certification process for drug and medical device manufacturing
Strategic Initiatives
Domestic Market Development
Management is actively developing managed care agreements with southeastern states to manage Medicaid wound care patients. These partnerships would provide the Company's Wound Closure System, products, and protocols, resulting in substantial cost savings for state Medicaid programs.
International Expansion
The Company is pursuing distribution opportunities in Asian and Middle Eastern markets through negotiations with regional distributors.
UAE Market Development Agreement:
•
Agreement dated June 11, 2023, with First Forte Consultancy (UAE)
•
Total value: $45,000
•
Services: Meeting facilitation and roadshows for potential distribution clients
•
Payment structure: $22,500 paid June 15, 2023; balance due upon completion
•
Expected completion: Fiscal year ending March 31, 2026
Competitive Advantage
Regenerex Pharma maintains significant competitive advantages through:
•
Proprietary QBx™ technology with proven clinical efficacy
•
Superior closure rates compared to existing solutions
•
Cost-effective treatment protocols
•
Comprehensive product portfolio addressing multiple wound types
•
Strategic positioning within evolving reimbursement landscape
•
Manufacturing capabilities and regulatory compliance
Executive Leadership
Regenerex Pharma Inc. maintains a comprehensive C-suite leadership structure comprising the Chief Executive Officer, Chief Financial Officer, Chief Development Officer, Chief Revenue Officer, Chief Clinical Director, Chief Research & Development Officer, Chief Creative Officer, and Vice President of International Operations.
8
Corporate Facilities and Real Estate
The Company operates under a strategic leasing model for its facilities. The primary corporate headquarters is located at 114 Main Street, Gordonsville, TN 38653, This property is secured through a lease agreement, allowing for operational flexibility and capital preservation.
We have an identity office at 5348 Vegas Drive #177, Las Vegas, Nevada 89108.
Manufacturing Operations
Regenerex Pharma Inc. employs an asset-light manufacturing strategy, utilizing leased production equipment and facilities rather than capital-intensive ownership. Current lease arrangements for production infrastructure extend through June 30, 2028, providing operational stability while maintaining financial flexibility.
Market Strategy and Distribution
Healthcare Partnerships
Management is actively developing managed care agreements with southeastern state governments to provide comprehensive wound care management for Medicaid populations. The Company's integrated Wound Closure System encompasses proprietary products, clinical protocols, and software solutions designed to deliver significant cost savings for state Medicaid programs.
International Expansion
The Company is pursuing strategic partnerships with distributors across Asian and Middle Eastern markets to expand global market penetration and diversify revenue streams.
Revenue Diversification
Regenerex anticipates generating revenue from multiple healthcare sectors, including:
•
U.S. Government-funded home care service providers
•
State Medicaid Programs
•
International Healthcare Programs
•
Veterans Administration
•
Correctional facility healthcare systems
•
Home Health Care Providers
•
Medicare reimbursement programs
Competitive Positioning
Wound Closure System Technology
Regenerex's proprietary Wound Closure System creates an optimal healing environment for wound closure through advanced biotechnology. The Company's unique approach addresses chronic, non-healing wounds through protease down-regulation and comprehensive wound bed preparation.
QBx™ Platform
The QBx™ technology represents a breakthrough in wound care, uniquely positioned in the market for its ability to successfully treat chronic, non-healing wounds through protease down-regulation. Unlike conventional wound dressings such as hydrocolloids and collagens that merely absorb wound fluids, Regenerex's solutions actively modify the cellular environment rather than simply providing protective coverage.
Market Differentiation
The Company maintains a significant competitive advantage as no other currently available products successfully heal chronic, non-healing wounds through the Company's proprietary mechanisms of action.
9
Intellectual Property Portfolio
Patent Protection
Regenerex has secured primary patent rights for its Wound Closure System and Wound Care Platform. The Company maintains two additional patents pending for antimicrobial properties and acceleration of acute and surgical wound healing.
Trademark Portfolio
The United States Patent and Trademark Office has approved multiple trademarks for the Company, with additional trademark protections secured in various international jurisdictions.
Digital Assets
The Company has secured strategic domain names including regenerexpharmainc.com and regenerexpharma.com to support its digital presence and brand protection strategy.
Regulatory Compliance Framework
Regenerex Pharma Inc. operates within a comprehensive regulatory environment overseen by multiple authorities including:
•
Food and Drug Administration (FDA)
•
Federal Trade Commission (FTC)
•
Various federal, state, and local regulatory bodies
•
International regulatory authorities in markets where products are distributed
Compliance Areas
Regulatory oversight encompasses multiple operational aspects including:
•
Product efficacy validation
•
Ingredient and product safety protocols
•
Manufacturing standards and quality control
•
Labeling and packaging requirements
•
Marketing and advertising compliance
•
Product shipment and disposal procedures
•
Comprehensive safety management systems
WHERE YOU CAN FIND MORE INFORMATION
You are advised to read this Form 10-K in conjunction with other reports
and documents that we file from time to time with the SEC. In particular,
please read our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K
that we file from time to time. You
may obtain copies of these reports directly from us or from the SEC at the
SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and
you may obtain information about obtaining access to the Reference Room by
calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information
for electronic filers at its website http://www.sec.gov.
10